Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : J&J Cancer Drug Zytiga Now Backed For Publicly Funded Use In UK

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2012 | 11:11am CEST

The U.K.'s health-care cost-effectiveness regulator Wednesday reversed an earlier decision and approved the publicly funded use of Johnson & Johnson's (JNJ) prostate-cancer pill Zytiga, after the U.S. company cut its price further.

Also known as abiraterone, Zytiga removes the prostate cancer tumor's supply of testosterone, preventing it from growing further and potentially extending a patient's life by more than three months. The medicine was rejected for use in the U.K. in February on grounds its terms of use wouldn't offer value for money.

Andrew Dillon, chief executive of the U.K.'s National Institute for Health and Clinical Excellence, or NICE, Wednesday said the manufacturer subsequently submitted fresh information, including a revised patient access scheme containing a deeper price discount to the National Health Service and more information about which patients would most benefit from its use and how many patients could receive the drug.

"These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS," Dillon said in a statement. "It is an effective treatment, potentially extending life by more than three months, and it also allows patients to be treated at home as it can be taken orally."

Abiraterone costs GBP2,930 for a 30-day supply of 120 tablets. NICE didn't specify the size of the price cut offered by Johnson & Johnson.

Zytiga was approved by U.S. and European drug regulators last year. It is set to generate peak-year sales of $910 million.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
08/17 JOHNSON & JOHNSON : Ethicon Transvaginal Mesh Lawsuits Move Forward in Pennsylva..
08/17 JOHNSON & JOHNSON : Announces Partnership with CSIR IMTECH to Develop Innovative..
08/17 JOHNSON & JOHNSON (NYSE : JNJ) Denies Talc Powder Ovarian Cancer-Link In Califor..
08/17 Chinas HitGen bags new drug discovery deal with Aduro
08/17 JOHNSON & JOHNSON : Cerecor CEO retires after scoring Johnson & Johnson license ..
08/16 INSIDER TRADING ACTIVITY NEVRO CORP. : NVRO) – CFO Sold 7,000 shares of St..
08/15 JOHNSON & JOHNSON : candal' of vaginal mesh removal rates revealed by NHS record..
08/14 JOHNSON & JOHNSON : to Participate in 2017 Morgan Stanley Global Health Care Con..
08/14 JOHNSON & JOHNSON : Duct tape evolves from ammo boxes to artwork
08/12 JOHNSON & JOHNSON : Chinese medical expert cautions against premature approval o..
More news
News from SeekingAlpha
08/17 Dividend Growth Stocks Going Ex-Div August 21-25th
08/17 45 $100+ Billion Companies In The S&P 500
08/16 Very Cautious On AbbVie's Fundamentals
08/16 Half Million Dollar Income Portfolio - Keep Living The Dream
08/16 Biogen's Alzheimer's Hope Tops The Sector's Most Valuable Pipeline Projects
Financials ($)
Sales 2017 75 842 M
EBIT 2017 22 815 M
Net income 2017 16 213 M
Debt 2017 17 708 M
Yield 2017 2,52%
P/E ratio 2017 22,15
P/E ratio 2018 18,01
EV / Sales 2017 4,94x
EV / Sales 2018 4,48x
Capitalization 357 079 M
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 136 $
Spread / Average Target 2,5%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.48%357 079
NOVARTIS10.59%220 515
ROCHE HOLDING LTD.5.37%218 264
PFIZER1.45%198 663
MERCK AND COMPANY5.05%171 005
SANOFI7.62%122 810